You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

CLINICAL TRIALS PROFILE FOR LARONIDASE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for laronidase

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00144768 ↗ A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients Completed BioMarin/Genzyme LLC Phase 4 2004-07-01 The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate.
NCT00144768 ↗ A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients Completed Genzyme, a Sanofi Company Phase 4 2004-07-01 The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate.
NCT00176891 ↗ Stem Cell Transplant w/Laronidase for Hurler Completed Masonic Cancer Center, University of Minnesota Phase 2 2004-03-01 The investigators hypothesize that weekly infusions of Laronidase ERT for 10-12 weeks prior to transplant and 8 weeks following transplant will result in a reduction of glycosaminoglycans (GAG) burden that is associated with decreased complications following transplant.
NCT00215527 ↗ Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I Terminated FDA Office of Orphan Products Development Phase 1 2005-11-01 The investigators are studying the use of enzyme replacement therapy into the spinal fluid for treatment of spinal cord compression in the Hurler-Scheie and Scheie forms of mucopolysaccharidosis I (MPS I). Funding source -- FDA OOPD
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for laronidase

Condition Name

Condition Name for laronidase
Intervention Trials
Mucopolysaccharidosis I 7
Hurler Syndrome 4
Hurler-Scheie Syndrome 3
Scheie Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for laronidase
Intervention Trials
Mucopolysaccharidosis I 10
Mucopolysaccharidoses 9
Syndrome 7
Lysosomal Storage Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for laronidase

Trials by Country

Trials by Country for laronidase
Location Trials
United States 11
Finland 2
Russian Federation 1
Brazil 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for laronidase
Location Trials
Minnesota 5
California 4
Wisconsin 1
Connecticut 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for laronidase

Clinical Trial Phase

Clinical Trial Phase for laronidase
Clinical Trial Phase Trials
Phase 4 2
Phase 2 1
Phase 1/Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for laronidase
Clinical Trial Phase Trials
Completed 6
Terminated 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for laronidase

Sponsor Name

Sponsor Name for laronidase
Sponsor Trials
Masonic Cancer Center, University of Minnesota 4
Patricia I. Dickson, M.D. 3
Genzyme, a Sanofi Company 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for laronidase
Sponsor Trials
Other 15
Industry 6
NIH 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.